These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23775577)

  • 1. An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer.
    di Martino E; Taylor CF; Roulson JA; Knowles MA
    Genes Chromosomes Cancer; 2013 Sep; 52(9):860-71. PubMed ID: 23775577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
    Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
    Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence in situ hybridization deletion mapping at 4p16.3 in bladder cancer cell lines refines the localisation of the critical interval to 30 kb.
    Bell SM; Zuo J; Myers RM; Knowles MA
    Genes Chromosomes Cancer; 1996 Oct; 17(2):108-17. PubMed ID: 8913728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer.
    Knowles MA; Aveyard JS; Taylor CF; Harnden P; Bass S
    Cancer Lett; 2005 Jul; 225(1):121-30. PubMed ID: 15922864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.
    Sibley K; Cuthbert-Heavens D; Knowles MA
    Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer.
    Bell SM; Shaw M; Jou YS; Myers RM; Knowles MA
    Genomics; 1997 Sep; 44(2):163-70. PubMed ID: 9299232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
    Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
    Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder.
    Knowles MA; Habuchi T; Kennedy W; Cuthbert-Heavens D
    Cancer Res; 2003 Nov; 63(22):7652-6. PubMed ID: 14633685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer.
    Czerniak B; Chaturvedi V; Li L; Hodges S; Johnston D; Roy JY; Luthra R; Logothetis C; Von Eschenbach AC; Grossman HB; Benedict WF; Batsakis JG
    Oncogene; 1999 Feb; 18(5):1185-96. PubMed ID: 10022124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic mapping and DNA sequence-based analysis of deleted regions on chromosome 16 involved in progression of bladder cancer from occult preneoplastic conditions to invasive disease.
    Yoon DS; Li L; Zhang RD; Kram A; Ro JY; Johnston D; Grossman HB; Scherer S; Czerniak B
    Oncogene; 2001 Aug; 20(36):5005-14. PubMed ID: 11526485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31.
    Simoneau M; Aboulkassim TO; LaRue H; Rousseau F; Fradet Y
    Oncogene; 1999 Jan; 18(1):157-63. PubMed ID: 9926930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of two regions on chromosome 4 in bladder carcinoma: definition of a critical 750kB region at 4p16.3.
    Elder PA; Bell SM; Knowles MA
    Oncogene; 1994 Dec; 9(12):3433-6. PubMed ID: 7970702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer.
    Hornigold N; Devlin J; Davies AM; Aveyard JS; Habuchi T; Knowles MA
    Oncogene; 1999 Apr; 18(16):2657-61. PubMed ID: 10353610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
    Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
    Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular evidence supporting field effect in urothelial carcinogenesis.
    Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
    Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer.
    Takle LA; Knowles MA
    Oncogene; 1996 Mar; 12(5):1083-7. PubMed ID: 8649800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.